1. Zreik, H, Li, J, Garson, AT. Etiology and danger of pericardial effusion in infants and children. Cardiol Young 1996; 6: 162–165.
Google Scholar | Crossref2. Waespe, N, Van Den Akker, M, Klaassen, RJ, et al. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. Haematologica 2016; 101: 1508–1515.
Google Scholar | Crossref | Medline3. Newman, M, Malla, M, Gojo, I. Azacitidine-Induced pericarditis: a case series. Pharmacother J Hum Pharmacol Drug Ther 2016; 36: 443–448.
Google Scholar | Crossref | Medline4. Goo, K, Uy, R, Roswarski, J. Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: a case report. J Oncol Pharm Pract 2019; 25: 1248–1252.
Google Scholar | SAGE Journals | ISI5. Bolin, EH, Tang, X, Lang, SM, et al. Characteristics of Non-postoperative pediatric pericardial effusion: a multicenter retrospective cohort study from the pediatric health information system (PHIS). Pediatr Cardiol 2018; 39: 347–353.
Google Scholar | Crossref | Medline6. van der Pal, HJ, van Dalen, EC, van Delden, E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30: 1429–1437.
Google Scholar | Crossref | Medline | ISI7. Gerds, AT, Gooley, TA, Estey, EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012; 18: 1211–1218.
Google Scholar | Crossref | Medline8. Medary, I, Steinherz, LJ, Aronson, DC, et al. Cardiac tamponade in the pediatric oncology population: treatment by percutaneous catheter drainage. J Pediatr Surg 1996; 31: 197–200.
Google Scholar | Crossref | Medline9. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
Google Scholar | Crossref | Medline | ISI